A promise to save 100 000 trauma patients

The Lancet

Volumn 380, Issue 9859, 2012, Pages 2062-2063

  Shakur, Haleema ^a   Roberts, Ian ^a   Piot, Peter ^a   Horton, Richard ^b   Krug, Etienne ^c   Mersch, Jeannot ^d  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b THE LANCET   (United Kingdom)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

^d European Federation of Road Traffic Victims ^*  (Luxembourg)

Author keywords

[No Author keywords available]

Indexed keywords

TRANEXAMIC ACID; ANTIFIBRINOLYTIC AGENT;

AFRICA; BLEEDING; CLINICAL TRIAL (TOPIC); COST EFFECTIVENESS ANALYSIS; DISABILITY ADJUSTED LIFE YEARS; DRUG EFFICACY; ECONOMIC ASPECT; HEALTH CARE COST; HEALTH CARE PERSONNEL; HEALTH CARE QUALITY; HEALTH SERVICE; HUMAN; INCOME; INJURY; NOTE; PATIENT CARE; PATIENT SAFETY; POPULATION; PRIORITY JOURNAL; SAFETY; SOUTH AND CENTRAL AMERICA; STANDARD; TRAFFIC ACCIDENT; ARTICLE; EXSANGUINATION;

ANTIFIBRINOLYTIC AGENTS; EXSANGUINATION; HUMANS; TRANEXAMIC ACID; WOUNDS AND INJURIES;

EID: 84871091952     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(12)62037-6     Document Type: Note

References (9)

1. Murray CJL, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2197-223.
2. Aeron-Thomas A, Jacobs GD, Sexton B, Gururaj G, Rahman F. The involvement and impact of road crashes on the poor: Bangladesh and India case studies. July, 2004. http://www.dfid.gov.uk/r4d/pdf/outputs/R7780.pdf (accessed Nov 12, 2012).
3. Peden M, Scurfield R, Sleet D, et al. World report on road traffic injury prevention. Geneva: World Health Organization, 2004.
4. The CRASH-2 Collaborators. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet 2010; 376: 23-32.
5. The CRASH-2 collaborators. The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. Lancet 2011; 377: 1096-101.
6. Guerriero C, Cairns J, Perel P, et al. Cost-effectiveness analysis of administering tranexamic acid to bleeding trauma patients using evidence from the CRASH-2 trial. PLoS One 2011; 6: e18987.
7. Ker K, Kiriya J, Perel P, Edwards P, Shakur H, Roberts I. Avoidable mortality from giving tranexamic acid to bleeding trauma patients: an estimation based on WHO mortality data, a systematic literature review and data from the CRASH-2 trial. BMC Emerg Med 2012; 12: 3.
8. Roberts I, Shakur H, Ker K, Coats T, CRASH-2 trial collaborators. Antifibrinolytic drugs for acute traumatic injury. Cochrane Database Syst Rev 2011; 1: CD004896.
9. Morris ZS, Wooding S, Grant J. The answer is 17 years, what is the question: understanding time lags in translational research. J R Soc Med 2011; 104: 510-20.